$48.83
Value $98.9B
GSK and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$48.83
Value $98.9B
$683.89
Value $254B
GSK (GSK) has a market value of $98.9B and Thermo Fisher Scientific (TMO) $254B. Over the last year, with dividends, GSK moved +6.5% and TMO +21.0%. The P/E is 12.9 for GSK and 35.9 for TMO. Dividend yield: GSK 3.64%, TMO 0.27%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
GSK$98.9B
TMO$254B
TMO is 2.6 times GSK
Revenue, 12 months
GSK$43.9B
TMO$47.4B
TMO is 1.1 times GSK
Net income, 12 months
GSK$7.7B
TMO$7.1B
GSK is 1.1 times TMO
Operating margin
GSK24.3%
TMO17.9%
6.4 points apart
ROIC
GSK18.6%
TMO8.2%
10.4 points apart
P/E
GSK12.9
TMO35.9
TMO is 2.8 times GSK
Dividend yield
GSK3.6%
TMO0.3%
3.3 points apart
5-year return
GSK+42.0%
TMO+8.9%
33.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
GSK+42.0%
TMO+8.9%
| Period | GSKWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +6.5%Price +2.8% | +21.0%Price +20.6% |
| 3 years since November 17, 2023 | +55.9%+16.0% a yearPrice +38.9% | +48.1%+14.0% a yearPrice +46.6% |
| 5 years since November 17, 2021 | +42.0%+7.3% a yearPrice +14.9% | +8.9%+1.7% a yearPrice +7.3% |
| 10 years since November 18, 2016 | +103.7%+7.4% a yearPrice +28.3% | +382.5%+17.0% a yearPrice +369.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
GSKGSKTMOThermo Fisher Scientific
| Price | $48.83 | $683.89 |
|---|---|---|
| Market value | $98.9B | $254B |
| Enterprise value (EV) | $119B | $289B |
| P/E | 12.9 | 35.9 |
| P/E, 5-year median | 13.1 | 32.7 |
| P/B | 4.6 | 4.6 |
| EV/EBIT | 11.2 | 34.2 |
| Free cash flow yield | 8.7% | 3.0% |
| Revenue, 12 months | $43.9B | $47.4B |
|---|---|---|
| Net income, 12 months | $7.7B | $7.1B |
| Free cash flow, 12 months | $8.6B | $7.6B |
| Earnings per share, 12 months | $3.73 | $18.96 |
| Revenue growth, year on year | 4.1% | 3.9% |
| Revenue growth a year, past | +6.1%over 5 years | +6.7%over 5 years |
| EPS growth a year, past | -0.5%over 5 years | +2.1%over 5 years |
| Gross margin | 72.4% | – |
|---|---|---|
| Operating margin | 24.3% | 17.9% |
| Net margin | 17.5% | 14.9% |
| ROIC | 18.6% | 8.2% |
| ROE | 35.8% | 13.4% |
| Cash | $4.6B | $6.1B |
|---|---|---|
| Total debt | $24.9B | $41.4B |
| Net debt / EBITDA | 1.5 | 3.7 |
| Interest cover | – | 5.5× |
| Dividend yield | 3.6% | 0.3% |
|---|---|---|
| Dividend per share, 12 months | $1.78 | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | 1.9% | 1.2% |
| Shareholder yield | 5.5% | 1.5% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($254B) is about 2.6 times GSK ($98.9B), at today's prices.
Since November 18, 2016, GSK's price moved +28.3% and TMO's +369.0%. With dividends: GSK +103.7% (+7.4% a year), TMO +382.5% (+17.0% a year). Past returns do not predict future ones.
The dividend yield at today's price is 3.64% for GSK and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid $1.78 and $1.84 per share.
At today's price, the P/E is 12.9 for GSK and 35.9 for TMO. The median of the last five years was 13.1 and 32.7, which shows where each stands against its own past.
Over the last twelve months, the net margin was 17.5% for GSK and 14.9% for Thermo Fisher Scientific, and the operating margin 24.3% and 17.9%. Revenue was $43.9B and $47.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.